Maas Biolab Wins World Cyclosporin Brain Formula Patents

ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Maas Biolab received United States Patent 7,446,093, European Union Patent 1,091,750 and Patents in India, Canada and New Zealand for its Mitogard® cyclosporin formulas. Mitogard® is designed for central nervous system delivery to treat neurodegenerative diseases, in particular amyotrophic lateral sclerosis (ALS). The patent covers the use of cyclosporin in DMSO formulations for neuroprotection and immunosuppression via cerebrospinal fluid (CSF), vascular, nasal and pulmonary delivery. The 19 European countries include Germany, France, the United Kingdom, Italy, Spain, Netherlands, Sweden and Switzerland.